# US 9,752,160 B2 · Use of non-subtype B gag proteins for lentiviral packaging

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,752,160 B2
- Document ID: US9752160B2
- Status: Granted
- Kind: B2
- Application number: 14/346,961
- Filed: 2012-09-25
- Published: 2014-08-21
- Granted: 2017-09-05
- Earliest claimed: 2011-09-26
- Assignees: Theravectys; Institut Pasteur
- Applicants: Theravectys; Institut Pasteur
- Inventors: Thi-Lan Tran; Pierre Charneau; Cecile Bauche
- Web page: https://patentgrep.com/patent/US9752160B2

## CPC

- C12N 15/86: Viral vectors
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- C07K 14/005: from viruses
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2740/16052: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2740/16222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2800/00: Nucleic acids vectors
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention encompasses a lentiviral packaging vector comprising a non-subtype B gag-pol sequence, particularly a subtype D gag-pol sequence. The invention further encompasses methods for making and using these vectors. The invention further encompasses lentiviral vector particles comprising HIV-1 non-subtype B Gag and/or Pol proteins.

## Claims

### Claim 1

A lentiviral packaging vector to generate a replication defective lentiviral vector particle, the vector lacking a site and encoding the Gag-Pol protein of HIV-1 NDK, wherein the Gag-Pol protein comprises the amino acid sequence of SEQ ID NO:2 wherein the coding sequence of the Gag-Pol protein is operably linked to an expression control sequence.

### Claim 2 (depends on 1)

The vector of claim 1, wherein the vector is a plasmid comprising a Cytomegalovirus promoter.

### Claim 3 (depends on 1)

A cell comprising the vector of claim 1.

### Claim 4 (depends on 3)

The cell of claim 3, wherein the vector is an integrative vector.

### Claim 5 (depends on 1)

A method for generating the packaging vector of claim 1, the method comprising inserting the nucleotide sequence encoding the Gag-Pol protein of HIV-1 NDK into a plasmid under the control of a non-HIV promoter to generate the packaging vector.

### Claim 6 (depends on 1)

A method for generating a lentiviral vector particle, the method comprising administering the packaging vector of claim 1 to a cell with a lentiviral vector comprising 5′ and 3′ lentiviral long terminal repeats and a sequence encoding lentiviral envelope.

### Claim 7 (depends on 6)

The method of claim 6, wherein the packaging vector and the lentiviral vector are plasmids.

### Claim 8 (depends on 6)

The method of claim 6, wherein the packaging vector is a non-integrative vector.

### Claim 9 (depends on 6)

The method of claim 6, wherein the packaging vector is an integrative vector.

### Claim 10

A lentiviral vector particle comprising Gag-Pol protein of HIV-1 NDK and VSV Env glycoproteins, wherein the Gag-Pol protein comprises the amino acid sequence of SEQ ID NO:2.

### Claim 11 (depends on 10)

The lentiviral vector particle of claim 10, wherein the lentiviral particle encodes a tumor antigen.

### Claim 12 (depends on 10)

The lentiviral vector particle of claim 10, wherein the lentiviral particle comprises an LTR deleted for U3 and R regions.

### Claim 13 (depends on 10)

The lentiviral vector particle of claim 10, wherein the lentiviral particle does not comprise HIV-1 Env proteins.